Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

NL0010696654
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG005SSJYH3
QURE
Uniqure NV
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Uniqure NV
ISIN
NL0010696654
TICKER
QURE
MIC
XNAS
REUTERS
QURE.OQ
BLOOMBERG
QURE US
Wed, 24.06.2026       uniQure
NL0010696654

LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 4,945,055 ordinary shares at a public offering price of $45...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.06.2026       uniQure
NL0010696654

LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $150 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.06.2026       uniQure
NL0010696654

~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.06.2026       uniQure
NL0010696654

Instrument ID [6620] (UQ1 - NL0010696654) suspended...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.06.2026       uniQure
NL0010696654

~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.05.2026       uniQure
NL0010696654

~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.04.2026       uniQure
NL0010696654

~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.04.2026       uniQure
NL0010696654

~ uniQure to host earnings call on Tuesday, May 5, 2026 at 8:30 a.m. ET ~...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       uniQure
NL0010696654

New York, New York--(Newsfile Corp. - April 13, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations of the...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       uniQure
NL0010696654

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.This press release f...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 13.04.2026       uniQure
NL0010696654

LOS ANGELES, April 12, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       uniQure
NL0010696654

LOS ANGELES, April 12, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Sec...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Sun, 12.04.2026       uniQure
NL0010696654

NEW YORK, April 12, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline....
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Sun, 12.04.2026       uniQure
NL0010696654

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UniQure To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in UniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Sat, 11.04.2026       uniQure
NL0010696654

New York, New York--(Newsfile Corp. - April 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased uniQur...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       uniQure
NL0010696654

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) (“uniQure” or the “Company”), if they purchased or otherwise acquired...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       uniQure
NL0010696654

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the “Class Period”). uniQure is a biotechnology company. For more information, submit a form, email attorney Phill...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       uniQure
NL0010696654

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UniQure To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in UniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partn...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       uniQure
NL0010696654

Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending SuitSAN FRANCISCO, April 9, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the fi...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       uniQure
NL0010696654

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encourag...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 09.04.2026       uniQure
NL0010696654

Philadelphia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) ("uniQure" or the "Company") on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       uniQure
NL0010696654

New York, New York--(Newsfile Corp. - April 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased uniQure...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       uniQure
NL0010696654

SAN FRANCISCO, April 7, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors w...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       uniQure
NL0010696654

New York, New York--(Newsfile Corp. - April 7, 2026) - Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.Should You Join The uniQure Class Action La...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       uniQure
NL0010696654

NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE). Shareholders who purchased shares of QURE during the class period listed are encouraged to contact...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       uniQure
NL0010696654

NEW YORK, April 7, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline....
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       uniQure
NL0010696654

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Secu...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       uniQure
NL0010696654

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UniQure To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in UniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       uniQure
NL0010696654

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who p...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Sun, 05.04.2026       uniQure
NL0010696654

SAN FRANCISCO, April 5, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors w...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       uniQure
NL0010696654

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In UniQure To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in UniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partn...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       uniQure
NL0010696654

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases.For more information, submit a form, email attorney...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       uniQure
NL0010696654

NEW ORLEANS, April 3, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) ("uniQure" or the "Company"), if they purchased or otherwise acquired the Company's shar...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       uniQure
NL0010696654

SAN FRANCISCO, April 3, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors w...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       uniQure
NL0010696654

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encourag...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       uniQure
NL0010696654

NEW YORK, April 1, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Cla...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       uniQure
NL0010696654

SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors w...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       uniQure
NL0010696654

NEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover loss...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       uniQure
NL0010696654

New York, New York--(Newsfile Corp. - March 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased uniQur...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       uniQure
NL0010696654

New York, New York--(Newsfile Corp. - March 31, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the ordinary shares of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclus...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       uniQure
NL0010696654

Philadelphia, Pennsylvania--(Newsfile Corp. - March 31, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) ("uniQure" or the "Company") on behalf of investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       uniQure
NL0010696654

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       uniQure
NL0010696654

NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE). Shareholders who purchased shares of QURE during the class period listed are encouraged to contact...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       uniQure
NL0010696654

Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending SuitSAN FRANCISCO, March 30, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the f...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       uniQure
NL0010696654

New York, New York--(Newsfile Corp. - March 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased uniQur...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       uniQure
NL0010696654

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V. Investor SummaryWho: uniQure N.V. (NASDAQ: QURE)What: Securities fraud class action lawsuit filedClass Period: September 24, 2025, and October 31, 2025Deadline to Seek Lead Plaintiff Status: April 13, 2026Key Lawsuit Allegations: Material misst...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       uniQure
NL0010696654

LOS ANGELES, March 30, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       uniQure
NL0010696654

LOS ANGELES, March 30, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Sec...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Sun, 29.03.2026       uniQure
NL0010696654

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partn...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink
Sat, 28.03.2026       uniQure
NL0010696654

NEW YORK and NEW ORLEANS, March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS...
Read more
uniQure
Technical Analysis Termsheets Terminal
Permalink